ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pneumococcal 20-Valent Conjugate Vaccine

Also written as “20vPnC”, “20-valent pneumococcal conjugate vaccine” and “Prevnar 20”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Respiratory Syncytial Virus Infections, led by 4 companies.

Drug pagePneumococcal 20-Valent Conjugate Vaccine: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 29, 201822 company-led studies, 5 open or runningNext primary completion: Jun 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only183 open or runningphase 3since Nov 29, 2018Nov 29, 2018Jun 10, 2027phase 1 · NCT07023081
GlaxoSmithKlineits history only20 open or runningphase 3since May 18, 2023Jun 3, 2022none ahead
LiteVax BV11 open or runningphase 1since Mar 30, 2025Mar 30, 2025none ahead
Merckits history only11 open or runningphase 1since Dec 10, 2025Dec 10, 2025Oct 24, 2028phase 1 · NCT07300267

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LiteVax BV only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2025First study: phase 1 study in Vaccine ReactionFirst studyNCT06986239 · 80 planned

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 20 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 20-Valent Conjugate Vaccine”name, by rule

Studies

The one study LiteVax BV leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06986239Vaccine Reaction1Not yet recruitingApr 1, 202680

How it is read

Names in the registry

  • “20vPnC”, 10 entries
  • “20-valent pneumococcal conjugate vaccine”, 7 entries
  • “Prevnar 20”, 2 entries
  • “PCV20 (Stage 1)”, 1 entry
  • “PCV20 (Stage 2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.